DigestRedComo funciona
Red
/
Empresas
La
No verificado

Latus Bio, Inc.

Sobre qué escribimos

BiotecnologíaCienciaIndustriaSaludSanidad

14 Comunicados de prensa

Ver todos los comunicados de prensa
30/10/2026
Eventos
Industria
Ciencia
Biotecnología
Farmacéutica
Sanidad
Salud
Latus Bio Announces New Preclinical Data Featuring High-Performing Engineered AAV Capsid Variants for Kidney and CNS Diseases at ESGCT 33rd Annual Congress
Fuente
Latus Bio, Inc.
Editor
Business Wire
1.00
0
28/10/2026
Salud
Biotecnología
Sanidad
Ciencia
Latus Bio Announces the Publication of a Predictive Computational Model of Huntington’s Disease (HD) Built on Human Data Along with Validating Preclinical Data, Supporting LTS-201 as a Potential Best-in-Class, Disease-Modifying Therapy for HD
Fuente
Latus Bio, Inc.
Editor
Business Wire
1.00
0
15/10/2026
Ciencia
Biotecnología
Sanidad
Farmacéutica
Salud
Eventos
Latus Bio to Participate In Chardan's 10th Annual Healthcare Conference
Fuente
Latus Bio, Inc.
Editor
Business Wire
1.00
0
13/10/2026
Salud
Sanidad
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Eventos
Industria
Latus Bio Announces Four Abstracts Selected for Presentation at the European Society of Gene and Cell Therapy 33rd Annual Congress
Fuente
Latus Bio, Inc.
Editor
Business Wire
1.00
0
05/10/2026
Eventos
Ferias y Congresos
Salud
Biotecnología
Sanidad
Medicina - Varios
Ciencia
Latus Bio Announces New Data Presentation at American Society of Nephrology (ASN) Kidney Week 2026
Fuente
Latus Bio, Inc.
Editor
Business Wire
1.00
0
09/09/2026
Mercado laboral
Salud
Biotecnología
Medicina - Varios
Ciencia
Farmacéutica
Latus Bio Appoints Donald Hayden as Chairman of the Board and Michael MacLean as Independent Director and Audit Committee Chair
Fuente
Latus Bio, Inc.
Editor
Business Wire
1.00
0
16/06/2026
Mercado laboral
Ciencia
Biotecnología
Medicina - Varios
Salud
Farmacéutica
Sanidad
Latus Bio Appoints Bethany Mancilla as Chief Business Officer
Fuente
Latus Bio, Inc.
Editor
Business Wire
1.00
0
04/05/2026
Ciencia
Biotecnología
Medicina - Varios
Salud
Farmacéutica
Sanidad
Latus Bio Announces $97 Million Series A Financing to Expand the Reach of Gene Therapy to Larger Populations
Fuente
Latus Bio, Inc.
Editor
Business Wire
1.00
0
28/04/2026
Eventos
Ferias y Congresos
Industria
Ciencia
Biotecnología
Sanidad
Salud
Medicina - Varios
Latus Bio to Present New Data at ASGCT 2026 Supporting Investigational Gene Therapy Approaches for Huntington’s Disease and CLN2 Disease
Fuente
Latus Bio, Inc.
Editor
Business Wire
1.00
0
02/12/2025
Industria
Ciencia
Biotecnología
Farmacéutica
Salud
Infancia
Ir de compras
Latus Bio Announces IND Clearance of LTS-101 for CLN2 Disease and Receipt of Fast Track, Orphan Drug, and Rare Pediatric Disease Designations
Fuente
Latus Bio, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0